Better Hep C Test to Guide Therapy Is ApprovedMarch 8, 2013
Roche Gets FDA Approval For Hepatitis-C Therapy Response
Published March 06, 2013 | Dow Jones Newswires
Roche Holding AG (ROG.VX) Wednesday said has received approval from the U.S. Food and Drug Administration for a next-generation viral load test to be used in the management of patients with chronic hepatitis C virus (HCV) infection.
- The COBAS AmpliPrep/COBAS TaqMan HCV Test, v2.0 provides a novel dual-probe approach, for an extra layer of protection in detecting and quantifying the virus.
- The test is designed to accurately determine the amount of hepatitis C virus ribonucleic acid (RNA) in order to assess a patient’s response to antiviral therapy.
Continue reading this entire article: